Antitope Ltd focuses on developing protein-based therapeutics that do not trigger an immune response in the body. As a biotechnology research company, their primary goal is to create innovative solutions for medical treatments by engineering proteins that are less likely to be recognized as foreign by the immune system. This approach could potentially improve the effectiveness and safety of protein-based drugs, addressing a significant challenge in the field of biotechnology. By reducing the risk of immune reactions, Antitope aims to enhance the therapeutic potential of these protein-based treatments and contribute to advancements in the field of biomedicine.